Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](BioCryst Pharmaceuticals)"
Count: 53
Selected: 0
| NCT ID | Title |
|---|
| NCT05741346 | Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT05453968 | Berotralstat Treatment in Children With Hereditary Angioedema | ||
| NCT05162066 | BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW) | ||
| NCT05116787 | BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy | ||
| NCT05116774 | BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy | ||
| NCT04933721 | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | ||
| NCT04702568 | A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04428632 | Oral Berotralstat Expanded Access Program | ||
| NCT04330534 | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH | ||
| NCT03891420 | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | ||
| NCT03873116 | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan | ||
| NCT03800173 | A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 | ||
| NCT03485911 | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE | ||
| NCT03472040 | A Long Term Safety Study of BCX7353 in Hereditary Angioedema | ||
| NCT03240133 | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema | ||
| NCT03202784 | A Relative Bioavailability Study of Two Formulations of BCX7353 | ||
| NCT03136237 | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions | ||
| NCT02870972 | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema | ||
| NCT02819102 | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates | ||
| NCT02670720 | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema | ||
| NCT02635724 | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza | ||
| NCT02448264 | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers | ||
| NCT02369159 | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza | ||
| NCT02319772 | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 | ||
| NCT02303626 | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks | ||
| NCT02218294 | Study to Determine How BCX4161 is Metabolized and Eliminated by the Body | ||
| NCT02125162 | A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 | ||
| NCT01984788 | Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE | ||
| NCT01407874 | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency | ||
| NCT01265264 | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol | ||
| NCT01224795 | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. | ||
| NCT01129648 | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout | ||
| NCT00985127 | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout | ||
| NCT00958776 | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza | ||
| NCT00957996 | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza | ||
| NCT00705406 | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza | ||
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00610935 | Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza | ||
| NCT00501735 | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma | ||
| NCT00486980 | Intramuscular Peramivir for the Treatment of Uncomplicated Influenza | ||
| NCT00453999 | Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza | ||
| NCT00419263 | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. | ||
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | ||
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | ||
| NCT00289549 | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | ||
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | ||
| NCT00098332 | Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma | ||
| NCT00073944 | BCX-1777 in Treating Patients With Refractory Cancer | ||
| NCT00061880 | BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma |
